Insulin Signaling Through the Insulin Receptor Increases Linear Growth Through Effects on Bone and the GH–IGF-1 Axis
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad491 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Marinna C Okawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Human Growth Hormone, Hyperinsulinism. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Context
Childhood overnutrition is associated with increased growth and bone mineral density (BMD) vs the opposite for undernutrition. The role of insulin receptor (InsR) signaling in these phenotypes is unclear. Rare disease patients with hyperinsulinemia and impaired InsR function (homozygous [−/−] or heterozygous [+/−] INSR pathogenic variants, type B insulin resistance [TBIR]) model decreased InsR signaling, while patients with intact InsR function (congenital generalized lipodystrophy, CGL) model increased InsR signaling.
Objective
This work aimed to understand mechanisms whereby InsR signaling influences growth.
Methods
A cross-sectional comparison was conducted of CGL (N = 23), INSR−/− (N = 13), INSR+/− (N = 17), and TBIR (N = 8) at the National Institutes of Health. Main outcome measures included SD scores (SDS) for height, body mass index, insulin-like growth factor (IGF)-1, and BMD, and IGF binding proteins (IGFBP)-1 and -3.
Results
INSR-/− vs CGL had higher insulin (median 266 [222-457] vs 33 [15-55] mcU/mL), higher IGFBP-1 (72 350 [55 571-103 107] vs 6453 [1634-26 674] pg/mL), lower BMI SDS (−0.7 ± 1.1 vs 0.5 ± 0.9), lower height SDS (−1.9[−4.3 to −1.3] vs 1.1 [0.5-2.5]), lower BMD SDS (−1.9 ± 1.4 vs 1.9 ± 0.7), and lower IGFBP-3 (0.37 [0.19-1.05] vs 2.00 [1.45-2.67] μg/mL) (P < .05 for all). INSR +/− were variable. Remission of TBIR lowered insulin and IGFBP-1, and increased IGF-1 and IGFBP-3 (P < .05).
Conclusion
Patients with hyperinsulinemia and impaired InsR function exhibit impaired growth and lower BMD, whereas elevated InsR signaling (CGL) causes accelerated growth and higher BMD. These patients demonstrate that insulin action through the InsR stimulates direct anabolic effects in bone and indirect actions through the growth hormone (GH)–IGF-1 axis. TBIR patients exhibit abnormalities in the GH axis that resolve when InsR signaling is restored, supporting a causal relationship between InsR and GH axis signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Marissa Lightbourne, Rebecca J Brown
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Okawa, M. C., Tuska, R. M., Lightbourne, M., Abel, B. S., Walter, M., Dai, Y., Cochran, E., & Brown, R. J. (2023). Insulin Signaling Through the Insulin Receptor Increases Linear Growth Through Effects on Bone and the GH–IGF-1 Axis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad491
Vancouver
Okawa MC, Tuska RM, Lightbourne M, Abel BS, Walter M, Dai Y, et al. Insulin Signaling Through the Insulin Receptor Increases Linear Growth Through Effects on Bone and the GH–IGF-1 Axis. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad491
BibTeX
@article{Okawa2023,
author = {Okawa, Marinna C and Tuska, Rebecca M and Lightbourne, Marissa and Abel, Brent S and Walter, Mary and Dai, Yuhai and Cochran, Elaine and Brown, Rebecca J},
title = {Insulin Signaling Through the Insulin Receptor Increases Linear Growth Through Effects on Bone and the GH–IGF-1 Axis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad491}
}
EUVIMED